title: [Efficacy comparison between Ph⁺ ALL patients treated with chemotherapyplus tyrosine kinase inhibitors followed by allo-HSCT and Ph-ALL patients with allo-HSCT: a case control study from a single center].
abstract: OBJECTIVE
  To compare the efficacy of the Ph⁺ acute lymphoblastic leukemia (ALL)patients treated with combination of tyrosine kinase inhibitors (TKI)and chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) and Ph⁻ ALL patients with allo-HSCT.
  
  
  METHODS
  A total of 19 Ph⁺ALL patients were matched with 19 Ph⁻ALL patients from 55 B-ALL patients receiving allo-HSCT in our hospital between January 2003 and August 2014 and were analyzed retrospectively.
  
  
  RESULTS
  Gender, median age, number of patients with blood white count more than 30 × 10⁹/L, number of patients with meningeal leukemia, disease status before allo-HSCT, period of allo-HSCT, the source of stem cell from donors, HLA disparities between donor and recipient, conditioning regimens and number of infused mononuclear cells and CD34⁺ cells were comparable between two groups of Ph⁺ and 19 Ph⁻ALL patients. The median time of engraftment of neutrophil cells was 12 days versus 13 days (P= 0.284) and that of platelet 14 days versus 17 days (P=0.246), which were comparable between two groups. The estimated 3-year overall survival (OS) in Ph⁺ and Ph⁻ALL groups was (67.5 ± 12.4)% versus (74.3 ± 11.4)% (P=0.434) and 3-year disease free survival (DFS)was (67.8 ± 12.4)% versus (74.3 ± 11.4)% (P= 0.456), respectively. The cumulative incidence of degree Ⅱ-Ⅳ acute graft-versus-host disease (aGVHD)in Ph⁺ and Ph⁻ ALL group was (15.8±8.4)% versus (21.1 ± 9.4)% (P=0.665)and that of degree Ⅲ-Ⅳ aGVHD was (5.6 ± 5.4)% versus (11.5 ± 7.6)% (P=0.541), respectively. The cumulative incidence of cGVHD was (44.1 ± 14.0)% in Ph⁺ALL group versus (44.1 ± 13.0)% in Ph⁻ALL group (P=0.835) and that of extensive cGVHD was (13.1 ± 8.7)% versus (6.2 ± 6.1)% (P=0.379), respectively. The cumulative relapse rate and the cumulative non-relapse rate in both group also have no statistical difference [(10.8 ± 7.2)% versus (20.0 ± 10.7)% (P=0.957) and (23.9 ± 12.4)% versus (7.1±6.9)% (P=0.224), respectively].
  
  
  CONCLUSIONS
  The efficacy of Ph⁺ALL treated with combination of chemotherapy and TKIs and followed by allo-HSCT is comparable to that of Ph⁻ALL with allo-HSCT.
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Jian
authors: J
authors: Hu
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Lihong
authors: L
authors: Wang
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Yuan
authors: Y
authors: Li
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Zhixiang
authors: Z
authors: Qiu
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Weilin
authors: W
authors: Xu
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Yuhua
authors: Y
authors: Sun
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Yue
authors: Y
authors: Yin
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Wei
authors: W
authors: Liu
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Jinping
authors: J
authors: Ou
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Mangu
authors: M
authors: Wang
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Wensheng
authors: W
authors: Wang
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Zeyin
authors: Z
authors: Liang
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Xinan
authors: X
authors: Cen
authors: Department of Hematology, Peking University First Hospital, Beijing 100034, China.
authors: Hanyun
authors: H
authors: Ren
mesh_terms: D018572:Disease-Free Survival; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D012189:Retrospective Studies
chemical_list: D011505:Protein-Tyrosine Kinases